Plans to issue a digital vaccination certificate to people who have been jabbed were announced last week, but so far details have been sparse. Spotlight spoke to several experts to get their views on what we know about the certificates so far.
Government can avoid the overwhelming of health services and minimise death in an anticipated fourth COVID-19 wave in November/December by getting 90% of people in South Africa over 35 years old vaccinated before then. Life could then return to normal by Christmas, even with ongoing SARS-CoV-2 circulation, contends vaccinologist Professor Shabir Madhi.
Dr Nicholas Crisp is a deputy director-general in the National Department of Health and the person responsible for coordinating South Africa’s COVID-19 vaccine rollout. Crisp spoke to Chris Bateman about challenges with the rollout and his wife and daughters getting sick with COVID-19.
South Africa’s COVID-19 vaccination programme currently requires that people enter an identity number when registering on government’s electronic system and present an identity document when they go to get jabbed. This makes it hard for homeless people without IDs to get vaccinated. Siyabonga Kamnqa reports from the streets of Cape Town.
As the country is still calculating the tally of the vaccine stock and medicines stolen in last week’s unrest in KwaZulu-Natal and Gauteng, there is still a lot of uncertainty about plans to restore medicine security.
Over five million people in South Africa have so far received at least one shot of a COVID-19 vaccine. Elri Voigt unpacks how the vaccination rollout is going in South Africa’s nine provinces. Though the numbers do not tell the full story and provinces face different challenges, indications are that Limpopo, Western Cape, Eastern Cape, and KwaZulu-Natal are doing well, while Mpumalanga is struggling.
The two vaccines used in South Africa’s vaccination programme, those from Johnson & Johnson and Pfizer/BioNTech, have both been shown to be highly effective against COVID-19, particularly in preventing hospitalisation and death. But protection may wane over time and new variants may or may not render these vaccines less effective. Adele Baleta unpacks what we do and do not know about the potential need for booster shots and surveys some of the studies that will help fill the gaps.
On Monday President Cyril Ramaphosa announced that South Africa will host the first World Health Organization-backed COVID-19 mRNA vaccine Technology Transfer Hub – an initiative designed to get the production of mRNA vaccines off the ground in Africa. Parties involved in the hub expect to hear as early as next week whether pharmaceutical companies with mRNA COVID-vaccines for COVID-19 on the market – Moderna and Pfizer/BioNTech – will share their know-how with the hub. Chris Bateman reports for Spotlight.
An experimental COVID-19 vaccine currently in Phase I trials being run by the University of Cape Town has a unique design that might allow it to offer better protection against current and future variants of the SARS-CoV-2 virus. Elri Voigt provides an update on the trial and unpacks the science behind this vaccine candidate.
When South Africa’s rollout of the AstraZeneca vaccine was put on hold in early February, a scramble ensued to ensure healthcare workers could be protected. Chris Bateman spoke to Professor Glenda Gray about the behind-the-scenes negotiations that helped secure 500 000 doses of the Johnson & Johnson vaccine – almost all of which have now been used in the Sisonke study.
The decision to “pause” the rollout of vaccines is perplexing. Every day the rollout is delayed results in infections and deaths that could have been prevented.
25 heads of state, including South Africa’s President Cyril Ramaphosa, have called for the creation of an international pandemic treaty to strengthen global capacity to predict and respond to pandemic threats. But what should we make of this development, given that existing treaties have often been ignored during the COVID-19 crisis and recent efforts toward a research and development treaty for health products have floundered, asks Catherine Tomlinson.
